The biotechnology pharmaceutical company HIPRA has received a positive opinion from the European Medicines Agency (EMA) for its monovalent recombinant protein adjuvanted vaccine BIMERVAX® adapted to the LP.8.1 variant. The vaccine, once it receives the decision from the European Commission, will be available for active immunization against COVID-19 for individuals aged 16 years and older. At the same time, the EMA has also announced the extension to expand the indication of the vaccine to individuals aged 12 years and older, which is also pending the decision of the European Commission.

According to the World Health Organization (WHO), the activity of the SARS-CoV-2 virus has shown a global rebound in recent months. The organization notes that “since mid-February 2025, based on available sentinel site data, global SARS-CoV-2 activity has been increasing, with a test positivity rate reaching 11%, levels not observed since July 2024”¹. Although most detected cases present mild or moderate severity, this increase confirms that the virus continues to circulate significantly and reinforces the need to maintain epidemiological surveillance and vaccination campaigns to protect the most vulnerable groups.